WO2024062443A1 - Compositions pharmaceutiques - Google Patents

Compositions pharmaceutiques Download PDF

Info

Publication number
WO2024062443A1
WO2024062443A1 PCT/IB2023/059391 IB2023059391W WO2024062443A1 WO 2024062443 A1 WO2024062443 A1 WO 2024062443A1 IB 2023059391 W IB2023059391 W IB 2023059391W WO 2024062443 A1 WO2024062443 A1 WO 2024062443A1
Authority
WO
WIPO (PCT)
Prior art keywords
composition
ketamine
stabilizer
compositions
amount
Prior art date
Application number
PCT/IB2023/059391
Other languages
English (en)
Inventor
Reena Patel
Dinesh Shantilal Patel
Sachin Dinesh Patel
Shashikant Prabhudas Kurani
Milind Vinayak SATHE
Surjyanarayan Mandal
Original Assignee
Reena Patel
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Reena Patel filed Critical Reena Patel
Publication of WO2024062443A1 publication Critical patent/WO2024062443A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/186—Quaternary ammonium compounds, e.g. benzalkonium chloride or cetrimide

Definitions

  • Present invention relates to subcutaneous injectable compositions comprising Ketamine equivalent to Ketamine base 50mg/ml and a stabilizer.
  • the compositions exhibits altered Cmax but similar Tmax and similar Area under curve (AUC).
  • Invention also relates to the process to prepare subcutaneous injectable compositions comprising Ketamine and a stabilizer.
  • Ketamine Hydrochloride in the form of injection is used as a general anesthetic to prevent pain and discomfort during medical tests or procedures, or minor surgery.
  • Several applications of Ketamine and its salts are being tried in several clinical trials. It is of great relief to patients suffering from Complex regional pain syndrome i.e. a poorly understood condition where a person experiences persistent severe and debilitating pain and in management of pain. Pain Management Specialists rely on Ketamine for Palliative care, to treat Oncology Chronic pain and such other pains. It is useful to treat treatment resistant depression. This wonder drug has several other applications. But it is also associated with some side effects.
  • ketamine hydrochloride Common known side effects of ketamine hydrochloride include blurred vision, double vision, dream-like feeling, dizziness, drowsiness, jerky muscle movements, loss of appetite, nausea, vomiting, sleep problems such as insomnia. Other side effects include hallucinations, severe confusion and extreme fear unusual thoughts and alike.
  • Ketamine may interact with barbiturates and other narcotics if administered to the patient.
  • the presence of Ketamine or its quantity in blood after it is injected is somewhat unpredictable.
  • Ketamine or Ketamine Hydrochloride is a potent molecule and is administered under a physician's supervision.
  • the initial dose of ketamine administered intravenously varies from 1 mg/kg to 4.5 mg/kg.
  • the average amount of 2 mg/kg produces surgical anesthesia of about five to ten minutes.
  • the initial dose of ketamine administered intramuscularly (IM) varies from 6.5 to 13 mg/kg.
  • a dose of 10 mg/kg normally produces surgical anesthesia of about 12 to 25 minutes.
  • Ketamine injection is presently available in strengths of 10MG BASE/ML 50MG BASE/ML 100MG BASE/ML. Its solubility in water is 200mg/ml.
  • Ketamine is racemic mixture of 2 isomers and S(+) ketamine has been shown to be significantly shorter acting than racemic ketamine, which allows a faster wake-up after use as an anesthetic and easier titration when used for sedation and/ or analgesia. It is also known that single-shot systemic administration has a short-term effect only. [Pediatric Anesthesia 2005 15: 91-97, CHARLES LIN MD AND MARCEL E. DURIEUX MD PhD, Department of Anesthesiology, University of Virginia Health System Charlottesville, Charlottesville, VA, USA]
  • a single subanesthetic dose of ketamine reduces depressive symptoms. Patients experience transient dissociation and psychotomimetic side effects and hemodynamic changes that limit its clinical use.
  • Ketamine is known to have direct effects on free recall and recognition memory. Ketamine is known to produce significant levels of thought disorder and withdrawal-retardation in healthy volunteers. Ketamine is known to cause Changes in behavior and perception, acute perceptual and cognitive disturbances.
  • Ketalar injection states that it is formulated as a slightly acid (pH 3.5-5.5) sterile solution for intravenous or intramuscular injection in concentrations containing the equivalent of either 10, 50 or 100 mg ketamine base/milliliter and contains not more than 0.1 mg/mL Phemerol® (benzethonium chloride) added as a preservative. 10 mg/mL solution has been made isotonic with sodium chloride.
  • WO2020232274 which discloses ketamine formulation for subcutaneous injection describes complexing with betacyclodextrins.
  • W 0/2022/109050 also describes complexing of ketamine with cyclodextrins.
  • EP3932393 claims a liquid pharmaceutical formulation comprising i). an active ingredient selected from ketamine and esketamine or a pharmaceutically acceptable salt thereof; ii). a cellulose ether; iii). glycerol; and iv) water.
  • Ketamine or its salt such as hydrochloride salt
  • side effects such as blurred vision, double vision, dream-like feeling, dizziness, drowsiness, jerky muscle movements, loss of appetite, nausea, vomiting, sleep problems such as insomnia and hence fullest medicinal potential of Ketamine or its salt such as hydrochloride salt is not fully realized.
  • side effects are due to sudden rise in Ketamine levels in the blood after administering injectable composition.
  • An injection of ketamine or its salt such as hydrochloride salt that is free from one or more side effects or undesired effects is not available.
  • there is urgent need to provide an injectable composition of Ketamine or its salt such as hydrochloride salt that is safe and effective and that shall have some predictable blood levels.
  • an object of the invention to provide an injectable composition comprising Ketamine equivalent to Ketamine base 50mg/ml which is safer and free from the side effects resulting due to sudden rise in Ketamine concentration in blood after administration of conventional injectable dosage form.
  • Still another object of the invention is to provide subcutaneous injectable compositions comprising Ketamine equivalent to Ketamine base 50mg/ml which exhibit Mean Cmax which is well above the concentration needed for therapeutic efficacy in patients with depression (0.5 mg/kg; 40 min infusion; 185 ng/ml), though it exhibits Cmax lower than currently marketed compositions.
  • Figure 1 provides a graph of blood concentrations of Ketamine in nanograms (ng)/ml on Y axis from Test and Reference compositions against time in hours on X axis.
  • the present invention provides an injectable composition comprising Ketamine equivalent to Ketamine base present as 50mg/ml hat exhibits AUC similar to that is exhibited by presently marketed injectable compositions although it may have different Cmax, preferably lower Cmax and similar Tmax.
  • the composition unexpectedly controls sudden rise of Ketamine in blood after being administered.
  • the composition is an aqueous composition.
  • the composition of present invention is free from the side effects resulting due to sudden rise in Ketamine concentration in blood after administration of conventional injectable dosage form.
  • the composition is a subcutaneous injectable composition.
  • the composition has a Cmax which is 80-100% of Cmax of marketed injectable compositions for subcutaneous use and AUCo-t is 80-100% of marketed injectable compositions but Tmax is similar wherein similar Tmax means 100+10% of Tmax of currently marketed subcutaneous injectable compositions.
  • the present invention provides a composition comprising Ketamine salt equivalent to Ketamine base 50mg/ml, a stabilizer and at least one pharmaceutically acceptable excipient.
  • the composition exhibits lower Cmax, but similar Tmax and similar AUC as that of conventional Ketamine Injectable composition.
  • the composition comprises stabilizer selected from but not limited to pyrrolidone potassium (PVPK), Diethylene Glycol Monoethyl Ether or alkyl derivatives thereof, Polyethylene Glycol (PEG), Sodium carboxymethyl cellulose.
  • PVPK pyrrolidone potassium
  • PEG Polyethylene Glycol
  • Sodium carboxymethyl cellulose a stabilizer
  • the stabilizer is PVPK.
  • the stabilizer is PVPK- 12 or PVPK-30.
  • the composition comprises Ketamine and stabilizer in a ratio of 12:1 to 2:1. In one embodiment, the ratio of Ketamine and stabilizer is 10:1 to 3:1. In another embodiment, the ratio of Ketamine and stabilizer is 7:1 to 3:1.
  • ratio of Ketamine to stabilizer is from 12.5:1 to 2.5:1, preferably from 10:1 to 3.33:1 and more preferably from 7.14:1 to 3.33:1.
  • the composition comprises at least one pharmaceutically acceptable excipient selected from but not limited to aqueous and or non-aqueous solvents, co-solvents, solubilizers, antioxidants, buffers/pH adjusting agents, chelating agents, preservatives, antimicrobials, and tonicity adjusting agents.
  • a pharmaceutically acceptable excipient selected from but not limited to aqueous and or non-aqueous solvents, co-solvents, solubilizers, antioxidants, buffers/pH adjusting agents, chelating agents, preservatives, antimicrobials, and tonicity adjusting agents.
  • the composition comprises chelating agent.
  • the chelating agent is selected from but not limited to disodium EDTA, sodium EDTA, calcium disodium EDTA, versetamide, calteridol calcium, and diethylenetriaminepenta acetic acid.
  • the chelating agent is disodium edetate.
  • the ratio of stabilizer to chelating agent in the composition is preferably 40:1 to 250:1. In one preferred embodiment the ratio is 50:1 to 160:1. In another preferred embodiment, the ratio is 50:1 to 150:1.
  • the composition comprises isotonicity agent.
  • the isotonicity agent is sodium chloride.
  • the ratio of stabilizer to isotonicity agent in the composition is preferably 2.5:1 to 14.29:1. In one preferred embodiment the ratio is 2.94:1 to 9.38:1. In another preferred embodiment the ratio is 3.68:1 to 9.38:1.
  • the composition further comprises a preservative.
  • the preservative is selected from but not limited to benzethonium chloride, benzyl alcohol, benzalkonium chloride, chlorobutanol, m-Cresol, methyl paraben, propyl paraben, and phenol.
  • the preservative is benzethonium chloride.
  • the amount of preservative in the composition is O.lmg/ml
  • the present invention provides a composition comprising Ketamine salt equivalent to Ketamine base 50mg/ml, a stabilizer, a chelating agent, and an isotonicity agent.
  • the composition comprises a stabilizer from 4 - 20 mg/ml, chelating agent from 0.05 to 0.2 mg/ml, and an isotonicity agent from 1.2 - 2mg/ml.
  • the stabilizer is selected from povidone K12 and or K30, chelating agent is disodium edetate, and isotonicity agent is sodium chloride.
  • the composition further comprises 0.10 mg/ml benzethonium chloride.
  • the present invention provides an aqueous injectable composition
  • composition of present invention eliminates at slower rate than currently marketed Ketamine injectable compositions.
  • composition of present invention is administered by intramuscular and intravenous routs.
  • the present invention provides use of a composition comprising Ketamine salt equivalent to Ketamine base 50mg/ml, a stabilizer and at least one pharmaceutically acceptable excipient for the treatment resistant depression and management of pain.
  • the present invention provides a method for the treatment of treatment resistant depression and management of pain, wherein the method comprising administering a composition of any of the preceding claims.
  • the composition provided in the present invention is a subcutaneous injectable composition.
  • the composition is provided in a pack size of 50mg Ketamine base/ml. Said pack size is equivalent to pack sizes such as 30mg Ketamine base in 0.6ml, 35mg Ketamine base in 0.7ml and 40mg Ketamine base in 0.8ml
  • the composition of present invention exhibits lesser or lower Cmax as compared to the currently marketed compositions indicating that the risk of concentration dependent- side effects is less with compositions of present invention.
  • the composition exhibits the mean Cmax of454.911 ng/mL which is well above the concentration needed for therapeutic efficacy in patients with depression (0.5 mg/kg; 40 min infusion; 185 ng/ml).
  • the invention provides method of preparation of a composition as claimed in any preceding claims, wherein the method comprises obtaining a solution dissolving chelating agent, stabilizer, isotonicity agent, optionally a preservative, and Ketamine salt in specific amounts in water having dissolved oxygen content 0.5mg/ml; and adjusting pH of the solution to 3.0 to 5.5, preferably 3-5.
  • the Cmax of the composition is 80-100% of Cmax of the marketed injectable composition for subcutaneous use and AUCo-t is 80-100% of marketed injectable composition, wherein Tmax is 100+10% of Tmax of currently marketed subcutaneous injectable composition.
  • the present invention relates to subcutaneous injectable pharmaceutical compositions comprising Ketamine or its salt such as hydrochloride and stabilizer with at least one pharmaceutically acceptable excipient.
  • the blood levels exhibited by the composition of the present invention, upon administration render it free from at least one of the undesired effects.
  • the pharmacokinetic profile of the composition of present invention was surprising. It was found that the composition of present invention has similar Tmax, but lower Cmax as compared to the conventional Ketamine 50mg/ml injectable compositions, However, AUC of the present composition and currently marketed injectable compositions of Ketamine was same.
  • Cmax means the highest concentration of a drug in the blood, after a dose is given
  • Tmax means the time it takes for a drug to reach the maximum concentration (Cmax) after administration of a drug
  • AUC meaning Area under curve which means the area under the plot of Blood/plasma concentration of a drug versus time after dosage. It represents the total drug exposure across time.
  • Two compositions are considered to be bioequivalent if the average bioavailability of the test composition is within (80% to 125%) that of the reference composition, with a certain assurance or if the estimated 90% confidence interval for the ratio of geometric means of the primary PK parameters (AUC and Cmax) is totally within the bioequivalence limits of 80% to 125%.
  • Lambda z/Terminal elimination rate constant- It describes the rate at which a drug is removed from the system/body. It is equivalent to the fraction of a substance that is removed per unit time measured at any particular instant.
  • the value 0.4 for Test formulation compared to 0.5 for Reference formulation indicates test composition is eliminated at slower rate than reference formulation and hence test formulation remains for longer duration in body.
  • MRT INF_obs (Observed Mean Residence time) -MRT obs represents the average time a molecule stays in the body.
  • Value is 2 for Test composition, whereas 1.9 of Reference composition indicates test compound remains for longer time in body compared to reference formulation.
  • Mrt Last - MRT represents the average time a molecule stays in the body when observed for 24 hrs.
  • Value is 2.1 for Test composition, whereas 2.0 of Reference composition indicating test composition remains for longer time in body compared to reference composition.
  • Vss obs is apparent volume of distribution at steady state.
  • the volume of distribution (Vd) is a pharmacokinetic parameter representing an individual drug’s propensity to either remain in the plasma or redistribute to other tissue compartments.
  • a drug with a high Vd has a propensity to leave the plasma and enter the extravascular compartments of the body.
  • a drug with a low Vd has a propensity to remain in the plasma.
  • Example 7 indicates that test formulation (Vss- 0.0018) has more distribution in body compartment compared to reference formulation (Vss- 0.0014).
  • the present invention provides clear, stable subcutaneous injectable compositions comprising Ketamine or salts thereof equivalent to Ketamine base up to 50 mg/ml and a stabilizer along with at least one pharmaceutically acceptable excipient selected from but not limited to aqueous and or non-aqueous solvents, cosolvents, solubilizers, anti-oxidants, buffers/pH adjusting agents, chelating agents, complexing agents, preservatives, antimicrobials, tonicity adjusting agents.
  • a pharmaceutically acceptable excipient selected from but not limited to aqueous and or non-aqueous solvents, cosolvents, solubilizers, anti-oxidants, buffers/pH adjusting agents, chelating agents, complexing agents, preservatives, antimicrobials, tonicity adjusting agents.
  • compositions of the present invention enable the composition to exhibit reduced Cmax, similar or different Tmax and similar AUC and thereby get rid of at least one undesired effect of currently marketed injections without compromising efficacy when a stabilizer is present along with Ketamine.
  • These substances or pharmaceutically acceptable ingredients which are essential for the compositions of the present invention and which cause favorable change in blood levels of Ketamine when compositions of the present invention are injected are termed as stabilizers. Incorporation of these substances enable compositions of the present invention to exhibit AUC similar to currently available compositions but do not manifest at least one of the undesirable effects or side effects as the Cmax of compositions of the present invention is lower while Tmax is similar.
  • compositions of the present invention enables them to be used by patients and it reduces dependence on strict use by physician if allowed by law of the land. It also enables to make use of fullest medicinal potential of the Ketamine molecule.
  • Polyethylene glycol of various grades such as PEG 300, PEG 400 or pharmaceutically acceptable different oils may also be used as Stabilizers.
  • Present invention is illustrated using PVPK as stabilizer.
  • PVPK is or povidone K or Polyvinylpyrrolidone (PVP) potassium, commonly called polyvidone, is a water- soluble polymer made from the monomer N-vinylpyrrolidone. PVPK is available in a range of molecular weights and related viscosities.
  • PVPK- 12 and PVPK30 grade Diethylene Glycol Monoethyl Ether or alkyl derivatives thereof, Polyethylene Glycol (PEG), Sodium CMC can also be used as Stabilizers.
  • the most critical ratio governing compositions of the present invention is that of Ketamine: Stabilizer. Ratio of Ketamine: Stabilizer from 12.5:1 to 2.5:1, more preferable being 10:1 to 3.33:1 and the most preferable ratio is 7.14:1 to 3.33:1 is necessary to prepare compositions of present invention where although Cmax is lower, AUC is similar.
  • Quantity of Ketamine is to be calculated based on Assay and LOD.
  • step 7 Cooled the above solution isotonic solution obtained in step 5 or preservative solution obtained in step 6 up to room temperature by applying chilled water in the jacket and nitrogen purging. Checked the temperature of solution. This is cooled solution.
  • Ketamine solution obtained in step 8 makes up the volume Ketamine solution obtained in step 8 to approximately 2.5 L with water for injection. Stir the solution for 10 minutes with nitrogen bubbling/Sparging and overlaying. Check the pH of solution of jacketed manufacturing tank. Limit of pH to 3.0 to 5.0. This is pH tested solution.
  • step 10 make up the final volume of pH tested solution obtained in step 9 up to 3 Liters using remaining quantity of water for injection from SS container to prepare unfiltered solution. Finally stir the unfiltered solution for 30 minutes with nitrogen bubbling/Sparging and overlaying. This is bulk solution.
  • Solvent in the present invention is water for injection.
  • suitable quantities of other aqueous or non-aqueous solvents such as Diethylene Glycol Monoethyl Ether (Transcutol) or alkyl derivatives thereof or various grades of Glycofurol.
  • Commonly used solvents such as water, ethanol can be employed to perform the invention.
  • Various types of alcohols can be employed as solvents and or solubilizers. Alcohols selected from monohydric alcohol or polyhydric alcohols may be employed. An alcohol other than monohydric alcohol is to be interpreted as polyhydric alcohol.
  • Examples of monohydric alcohol are any pharmaceutically acceptable single chain or branched chain alcohol having only one OH group. Suitable examples are ethyl alcohol or benzyl alcohol. Glycerin is example of polyhydric alcohol. There are many other polyhydric alcohols. One may use polyethylene glycol or some ether derivatives as good solubilizers.
  • Solvents can be solids or liquids. Solids when present in the form of solution in appropriate solvents also act as solubilizers. Ketamine salt used in the present invention and other ingredients used in the present invention are water soluble.
  • Solubilizers may be selected from but not limited to Transcutol 2 to 50%, PEG 300 up to 50%, PEG 400 up to 20.30%, Polysorbates or Tweens such as Tween 80. It may also comprise suitable vegetable oils as solvents. Alcohols such as Ethanol are good solubilizer. The concentration of Diethylene Glycol Monoethyl Ether or alkyl derivatives thereof in range 0.2% - 5% (v/v) act as solubilizers as well as stabilizers either alone or in combination with other stabilizers.
  • the invention provides therapeutically effective amount of Ketamine or salts such as hydrochloride salt in an aqueous composition suitable to be administered by subcutaneous route.
  • Composition of the present invention is ready-to-use composition of Ketamine or salts thereof in management of pain and treatment of treatment resistant depression.
  • the invention provides a simple and economical composition comprising Ketamine or its salts such as hydrochloride salt thereof equivalent to Ketamine base 50 mg/ml suitable for subcutaneous administration that is bioequivalent with conventionally available injectable compositions comprising Ketamine base 50mg/ml.
  • compositions of the present invention exhibit viscosity of 1.0 cps to 3.0 cps.
  • Glycofurol of various grades such as Glycofurol 75 upto 5%, may be used as solvent or cosolvent or solubilizer.
  • Tweens such as Tween 80 acts as surfactant or solubilizer.
  • the present invention optionally uses antioxidants selected from but not limited to thioglycerol, acetyl cysteine, butylated hydroxy anisole (BHA) and butylated hydroxy toluene (BHT), ascorbates, ascorbyl palmitate, methyl paraben, propyl paraben, thiomerosal and mixed Tocopheryl ingredient.
  • antioxidants selected from but not limited to thioglycerol, acetyl cysteine, butylated hydroxy anisole (BHA) and butylated hydroxy toluene (BHT), ascorbates, ascorbyl palmitate, methyl paraben, propyl paraben, thiomerosal and mixed Tocopheryl ingredient.
  • BHA butylated hydroxy anisole
  • BHT butylated hydroxy toluene
  • the invention may also comprise additional excipients like preservatives such as benzalkonium chloride, benzyl alcohol, m-cre
  • composition of present invention may also comprise the stabilizers such as polysorbate 80, 1-cysteine, diethanolamine, 1-methionine, sodium gluconate, sodium thioglycolate, triethanolamine and oleic acid.
  • stabilizers such as polysorbate 80, 1-cysteine, diethanolamine, 1-methionine, sodium gluconate, sodium thioglycolate, triethanolamine and oleic acid.
  • the isotony of the composition is obtained by adding a precisely calculated quantity of isotonicity agent or tonicity adjusting agent selected from sodium chloride, dextrose anhydrous, Glycerin, glucose, mannitol, sorbitol, potassium chloride or calcium chloride.
  • the most preferred isotonic agent is sodium chloride.
  • the ratio of stabilizer to isotonicity agent is 2.5:1 to 14.29:1, preferably being 2.94:1 9.38:1 and the more preferably being 3.68:1 to 9.38:1
  • the compositions of present invention having osmolality from about less than 100 to about 800 mOsm/kg.
  • the solution isotony or isotonicity is between 100 and 400 mOsm/kg is desirable and obtained. Techniques and processes to adjust the isotonicity or osmolality are known in the art and accordingly isotonicity should be adjusted.
  • the composition of present invention comprises chelating agents.
  • the chelating agents that may be used in formulation to chelate traces of metallic impurity may be selected from but not limited to disodium EDTA, sodium EDTA, Calcium disodium EDTA 0.2%, Versetamide 2.54%, Calteridol Calcium 0.023%, also Diethylenetriaminepenta Acetic Acid and ingredients alike.
  • theatio of stabilizer to chelating agent in the composition is 40:1 to 250:1, preferably 50:1 to 160:1 and the more preferably 50:1 to 150:1.
  • the ratio of stabilizer to chelating agent is critical for the compositions.
  • the composition comprises antimicrobial preservatives. In other embodiments, the composition does not have any preservatives.
  • the preservatives when present are selected from but not limited to benzethonium chloride 0.01%, benzyl alcohol up to 2%, benzalkonium chloride 0.02%, chlorobutanol 2.5 to 5%, m-cresol 0.1% to 0.3%, parabens like methyl paraben, propyl paraben up to 1%, phenol up to 0.45%. Some more excipients like 2-PhenoxyEthanol, Phenyl Mercuric Nitrate, Thiomersal and excipients alike or mixtures thereof. Benzyl alcohol acts as solvent also. In preferred embodiments the preservative used is benzethonium chloride.
  • Suitable surfactants such as Polysorbates/Tweens, sorbitan mono laurate, lecithin, povidone or other pharmaceutically acceptable surfactants may be used either individually or in combination to prepare compositions of the invention.
  • a pH close to the physiological one is recommended to minimize pain, irritation, and tissue damage.
  • Buffers optimize solubility and stability by adjusting the pH.
  • pH adjustment agents or buffers examples include but not limited to sodium, potassium or ammonium salt of a weak acid, a tris-(hydroxymethyl)-aminomethane, or Sodium citrate, Sodium phosphate, Sodium Hydroxide, Tris base-65, Tris acetate, Tris HC1 -65 or commonly known acetates, citrates, phosphates or a further physiologically active material acting as a buffer such as sodium hydroxide, hydrochloric acid, boric acid, citric acid, acetic acid, phosphoric acid, succinic acid, potassium hydroxide, ammonium hydroxide, magnesium oxide, calcium carbonate, magnesium carbonate, malic acid, potassium citrate, sodium phosphate, lactic acid, gluconic acid, tartaric acid, fumaric acid, diethanolamine, monoethanolamine, sodium carbonate, sodium bicarbonate, triethanolamine, or any combination thereof.
  • the stable aqueous injectable solution may comprise one or more pH adjusting agents in sufficient quantity to provide
  • compositions are filled, sealed, packed and provided in suitable containers made up of glass or plastic preferably of single compartment which may be composed of low density polyethylene (LDPE), high density polyethylene (HDPE), polypropylene (PP) or mixtures of polyethylene and polypropylene.
  • LDPE low density polyethylene
  • HDPE high density polyethylene
  • PP polypropylene
  • Preferably used glass material is USP type I glass (borosilicate glass) and type II glass.
  • the said composition may be provided in volume of less than 1 ml of single compartment or ready-to-use injection which can be diluted according to physiological use.
  • Containers used to contain compositions of present invention may be stoppered by rubber stoppers, closures or disc seals, screw-caps or cap-stopper combination seals closures.
  • compositions are subjected to sterilization process to achieve the sterile compositions.
  • the formulation is prepared and filled in article and is terminally sterilized by electron beam irradiation such as y-irradiation, natural light, microwave heat viz. moist heat sterilization, dry heat sterilization.
  • Autoclave sterilization may be preferred to achieve moist heat sterilization after final packaging. Typical cycle of autoclave to attain the sterilization of the final product is 121° C for 15 minutes.
  • compositions can be autoclaved at temperature ranging from 110° C to 130° C, preferably 115° C to 125° C for period of time ranging from 5 minutes to 30 minutes, preferably 10 minutes to 20 minutes. More preferably the autoclaving is done at 120° C to 122° C for 15 minutes.
  • compositions after sterilization were stored at different stability conditions as per the stability guidelines.
  • the compositions provide an accurate dose active.
  • composition is having pH ranging from 3.00 to 5.00 and viscosity is in between 1.0 cps to 3.0 cps.
  • the injectable compositions of the present invention exhibit AUC similar to that of currently marketed injectable compositions of Ketamine although Cmax is lower and Tmax is more or less similar.
  • the undesired effects associated with currently marketed injectable compositions of Ketamine are not associated with compositions of present invention although AUC is similar.
  • the compositions do not cause sharp spike of Ketamine as is caused by conventional compositions and hence are safe and effective.
  • the compositions of the present invention are suitable for administration by subcutaneous route.
  • the most critical ratio governing compositions of the present invention is that of Ketamine: Stabilizer. Ratio of Ketamine: stabilizer from 12.5:1 to 2.5:1, more preferable being 10:1 to 3.33:1 and the most preferable ratio is 7.14:1 to 3.33:1.
  • subcutaneous injectable compositions comprising Ketamine equivalent to Ketamine base 50mg/ml with stabilizer which exhibit lesser Cmax as compared to the currently marketed compositions indicating that the risk of concentration dependent- side effects is less with compositions of present invention.
  • subcutaneous injectable compositions comprising Ketamine equivalent to Ketamine base 50mg/ml with stabilizer which exhibit Mean Cmax of 454.911 ng/mL which is well above the concentration needed for therapeutic efficacy in patients with depression.
  • subcutaneous injectable compositions comprising Ketamine equivalent to Ketamine base 50mg/ml with stabilizer which exhibit same Tmax as that of the currently marketed formulation meaning the efficacy of onset of action is not compromised or delayed but is similar to that of marketed compositions.
  • compositions of the present invention comprise of stabilizer, an ingredient i.e. PVPK or PEG and other listed here before that have capability of rendering it not bioequivalent.
  • stabilizer an ingredient i.e. PVPK or PEG and other listed here before that have capability of rendering it not bioequivalent.
  • the invention also resides in specific quantities of stabilizer that ensures the compositions of the present invention are bioequivalent yet free from side effects associated with conventional injectable compositions because surprisingly it lowers the Cmax, does not impact Tmax and surprisingly maintains similar AUC.
  • compositions of the present invention are bioequivalent to currently marketed compositions.
  • Example 1 Ketamine subcutaneous composition. Batch size of 3 Liters was prepared for Trial A and for Trial G. Quantity expressed as mg/ml.
  • Example 2 Procedure to prepare composition in Example 1.
  • Disodium edetate Added and dissolved dispensed quantity of Disodium edetate followed by Povidone K12 in the jacketed manufacturing, tank. Rinsed the container of Disodium edetate two times with water for injection from SS vessel and added it in jacketed manufacturing tank. This is chelating agent solution.
  • Ketamine solution obtained in step 8 was made up to approximately 2.5 L with water for injection and Stirred for 10 minutes with nitrogen bubbling/Sparging and overlaying and checked pH of solution. Limit of pH to 3.0 to 5.0. This is pH tested solution.
  • step 10 Made up the final volume of pH tested solution obtained in step 9 up to 3 L by using remaining quantity of water for injection from SS container to prepare unfiltered solution. Stirred the unfiltered solution for 30 minutes with nitrogen bubbling/Sparging and overlaying. This is bulk solution.
  • Filtration is carried out to sterilize the composition by filtering through 0.22 mu filter to prepare filtered or sterilized solution.
  • Example 3 Compositions with varying stabilizer quantities. Quantity of each ingredient is expressed as (mg/mL)
  • Example 4 Analysis and Assay of Ketamine compositions was performed as per method of analysis described in IP-2022, Volume -II, Page no. 2667-2668.
  • Example 5 Example 1 composition G- 6 Month Stability at 25°C ⁇ 2°C/ 60% ⁇ 5% RH
  • Example 6 Example 1 Composition G: 6 Month Stability at 40°C ⁇ 2°C/ 75% ⁇ 5%RH
  • Example 7 Pharmacokinetic Parameters (mean +SD) of Ketamine test product and reference marketed formulation
  • Cmax of Test composition is 82.04% of Cmax of reference product.
  • Tmax of Test and Reference composition is identical.
  • AUCo-t of Test composition is 82.129% of Reference composition.
  • the value 0.4 of Lambda_z for Test composition compared to 0.5 for Reference composition indicate test composition is eliminating at slower rate than reference composition and hence test composition remains for longer duration in body.
  • Value 2 of MRTINF_obs for Test composition, and 1.9 for Reference composition indicates test composition remains for longer time in body compared to reference composition.
  • Value of MRT last is 2.1 for Test composition, whereas 2.0 for Reference composition indicating test compound remains for longer time in body compared to reference composition.
  • Values of Vss_obs indicate that Test composition (Vss- 0.0018) has more distribution in body compartment compared to reference composition (Vss- 0.0014).
  • T last Time of Last observed concentration indicates concentrations of analyte at 24hrs (last timepoint of blood collection.)
  • Example 8 Compositions with PEG-400, PVPK-30, PVPK-12: A Composition with PEG- 400, PVPK-30, PVPK-12 was prepared by a process of example 2. In one composition PEG- 400 was incorporated in an amount of 0.2ml/ml of composition. In another composition PVP K-30 was incorporated in an amount of 5.9 mg/ml of composition. In yet another composition PVPK-12 was incorporated in an amount of lOmg/mL. Other ingredients remaining same. Formulations were found stable.
  • Example 9 Study of blood concentrations of Ketamine in rats.
  • Figure 1 provides a graph of blood concentrations of Ketamine in nanograms (ng)/ml on Y axis from Test and Reference compositions against time in hours on X axis.
  • mice 24 rats (12 males and 12 females) were randomly allocated based on body weights to 2 different groups G1 and G2, each having 6 animals/sex. Following randomization, selected animals were identified by animal number written on base of tail.
  • the dose most commonly used in Humans is 0.5mg/kg.
  • the conversion factor for Rat is 6.17. So Rat equivalent dose is 3.1mg/kg.
  • Ketamine 50 Injection manufactured by Themis Medicare Ltd, a marketed formulation to receive 3.1mg/kg body weight by subcutaneous route.
  • the AUC was determined to understand the total exposure of the Ketamine concentrations to be remained in the blood, which will determine the dosing of the compounds.
  • AUCo to t for Test and reference formulation was found 692.979 ng/mL and 847.083, respectively.
  • Example 10 Behavioural testing comparing compositions of the invention with presently marketed Ketamine 50 injection 5 ml vial, Manufactured by Themis Medicare Limited (Generic name: Ketamine Hydrochloride Injection IP 50mg/ml)
  • G1 group was control group to whom normal saline was administered.
  • Composition of invention was administered and to group G3 marketed formulation was administered, subcutaneously in 3 doses ie 1.5mg/kg, 3mg/kg and 6mg/kg on three different days in ascending manner.
  • Dose volume did not exceed 1 mL/kg. Actual volume administered was calculated based on the recent body weight of each animal.
  • Open Field Test Animals were evaluated for Open field test, Learning and memory test (e.g. Y maze Test) and Functional observational battery test.
  • composition of the present invention have lesser inhibitory effect of locomotion and movements and that Composition of the present invention is better than the currently marketed formulation in terms of less deterioration of locomotor activity at a dose of 1.5mg/kg in rats.
  • Urination Number of urinations slightly increased in G3 group than in G2 group animals. It means G2 animals have possibly better muscle control than animals in G3. So at 1.5mg/kg, Composition of the present inventions have lesser side effects or is devoid of some effects present in marketed compositions.
  • compositions of the present inventions enable better muscle coordination and control than marketed compositions.
  • SRM spatial reference memory
  • composition of the present invention causes less deterioration of spatial memory as compared to the currently marketed formulation at low Dose (1.5 mg/kg) and Mid dose (3 mg/kg).
  • Functional observational battery :
  • Composition of the present invention is less affected by Composition of the present invention as compared to Ketamine marketed formulation at lower dose. It also means that Composition of the present invention at 1.5mg/kg dose has less potential for neurotoxicity as compared to the Ketamine marketed formulation.
  • composition of present invention is better than the currently marketed ketamine injectable formulation in terms of less deterioration of
  • SRM Spatial Reference Memory
  • SRM Spatial reference memory
  • SAP Spontaneous alteration performance
  • SAR Same Arm Return
  • SAP indicates that the animal is having a good working memory will remember the arms of the maze that it has already visited and will show a tendency to enter a less recently visited arm.
  • SRM indicates intact spatial reference memory, animal enters and spend more time in the novel arm compared to the other arms of the maze. Animals with impaired spatial reference memory will not be able to identify the novel arm.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La présente invention concerne des compositions pharmaceutiques injectables sous-cutanées comprenant de la kétamine ou son sel tel que le chlorhydrate de kétamine équivalent à la base de kétamine de 50 mg/ml et un stabilisant. L'invention concerne également un procédé de préparation desdites compositions. Les compositions selon la présente invention ont un profil pharmacocinétique typique. Les compositions selon la présente invention sont bioéquivalentes à des compositions injectables actuellement commercialisées mais ont une Cmax inférieure, une Tmax similaire et une AUC similaire. Les compositions selon la présente invention sont utiles dans le traitement de la dépression résistante au traitement et dans la gestion de la douleur.
PCT/IB2023/059391 2022-09-22 2023-09-22 Compositions pharmaceutiques WO2024062443A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN202221054235 2022-09-22
IN202221054235 2022-09-22

Publications (1)

Publication Number Publication Date
WO2024062443A1 true WO2024062443A1 (fr) 2024-03-28

Family

ID=88505108

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2023/059391 WO2024062443A1 (fr) 2022-09-22 2023-09-22 Compositions pharmaceutiques

Country Status (1)

Country Link
WO (1) WO2024062443A1 (fr)

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994023711A1 (fr) * 1993-04-13 1994-10-27 Gödecke Aktiengesellschaft Solutions stables de ketamine
US20090156562A1 (en) * 2005-11-14 2009-06-18 Winch Peter D Novel colored solutions of injectable drugs and their pharmaceutically acceptable salts
WO2020232274A1 (fr) 2019-05-15 2020-11-19 Bexson Biomedical, Inc. Formulation de kétamine pour injection sous-cutanée
EP3932393A1 (fr) 2020-07-03 2022-01-05 Alkaloid AD Skopje Formulation pharmaceutique
WO2022109050A1 (fr) 2020-11-18 2022-05-27 Bexson Biomedical, Inc. Formulations salines de composés pharmaceutiques à base d'agents complexants

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994023711A1 (fr) * 1993-04-13 1994-10-27 Gödecke Aktiengesellschaft Solutions stables de ketamine
US20090156562A1 (en) * 2005-11-14 2009-06-18 Winch Peter D Novel colored solutions of injectable drugs and their pharmaceutically acceptable salts
WO2020232274A1 (fr) 2019-05-15 2020-11-19 Bexson Biomedical, Inc. Formulation de kétamine pour injection sous-cutanée
US20210186896A1 (en) * 2019-05-15 2021-06-24 Bexson Biomedical, Inc. Ketamine formulation for subcutaneous injection
EP3932393A1 (fr) 2020-07-03 2022-01-05 Alkaloid AD Skopje Formulation pharmaceutique
WO2022109050A1 (fr) 2020-11-18 2022-05-27 Bexson Biomedical, Inc. Formulations salines de composés pharmaceutiques à base d'agents complexants

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
"CHARLES LIN MD AND MARCEL E. DURIEUX MD PhD", vol. 15, 2005, DEPARTMENT OF ANESTHESIOLOGY, article "Pediatric Anesthesia", pages: 91 - 97
DAVIS PARKE: "Ketamine hydrochloride (Ketalar)", CLINICAL PHARMACOLOGY AND THERAPEUTICS, vol. 11, no. 5, 4 September 1970 (1970-09-04), US, pages 777 - 780, XP093111338, ISSN: 0009-9236, DOI: 10.1002/cpt1970115777 *
IP-2022, vol. II, pages 2667 - 2668
WALLACH JASON ET AL: "Three Birds, One Excipient: Development of an Improved pH, Isotonic, and Buffered Ketamine Formulation for Subcutaneous Injection", PHARMACEUTICS, vol. 14, no. 3, 3 March 2022 (2022-03-03), pages 556, XP093016647, DOI: 10.3390/pharmaceutics14030556 *

Similar Documents

Publication Publication Date Title
PL207845B1 (pl) Spray donosowy do dostarczania kompozycji farmaceutycznej zawierającej fentanyl i zastosowanie soli fentanylu do wytwarzania środka leczniczego
JP4943550B2 (ja) 医薬組成物
DK2387389T3 (en) Composition for oral transmucosal administration of analgesic or antispasmodic molecules
EP1313511B1 (fr) Formulation d'un ester de testosterone pour le traitement de l'homme
CN107810000B (zh) 来氟米林的可注射药物组合物
AU2001291775A1 (en) Testosterone ester formulation for human use
JP2024023498A (ja) 一酸化窒素放出プロスタミドを含有する眼科用組成物
AU2012370410A1 (en) Drug delivery technology
EP4259098A1 (fr) Formulation liquide d'apixaban dans un faible volume de dose
WO2024062443A1 (fr) Compositions pharmaceutiques
US10646439B2 (en) Aqueous pharmaceutical formulation comprising propofol
US20210322345A1 (en) Midodrine hydrochloride oral solution and uses thereof
EP3441073B1 (fr) Composition médicinale comprenant du fulvestrant
EP2749266B1 (fr) Composition pharmaceutique injectable stable d'agoniste du récepteur de la vitamine D et son procédé de préparation
WO2019138162A1 (fr) Palonosétron pour le traitement ou la prévention de la nausée et des vomissements
US7632853B2 (en) Soluble, stable and concentrated pharmaceutical composition compromising ritonavir and process for preparing thereof
AU2020226862B2 (en) Naloxone formulations for sublingual and/or buccal administration
RU2781022C2 (ru) Офтальмологические композиции, содержащие простамид, высвобождающий окись азота
US7645765B2 (en) Use of moxaverin for treating erectile dysfunction, forms of dementia or diseases associated to an arteriosclerotic occlusion
KR20160090312A (ko) 조산 조건의 치료에서 사용을 위한 용량 단위의 조합
JPH07116039B2 (ja) 安定な塩酸トリメトキノール内用液剤
KR20150027160A (ko) 척추 투여용 과포화 아세타미노펜 주사 용액

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 23793032

Country of ref document: EP

Kind code of ref document: A1